Pcas SA
PAR:PCA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
8
8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Pcas SA
Pcas SA
Total Current Liabilities
Pcas SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Pcas SA
PAR:PCA
|
Total Current Liabilities
€217.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
14%
|
|
|
Sartorius Stedim Biotech SA
PAR:DIM
|
Total Current Liabilities
€873.8m
|
CAGR 3-Years
3%
|
CAGR 5-Years
16%
|
CAGR 10-Years
18%
|
|
|
Eurofins-Cerep SA
PAR:ALECR
|
Total Current Liabilities
€11m
|
CAGR 3-Years
12%
|
CAGR 5-Years
17%
|
CAGR 10-Years
5%
|
|
Pcas SA
Glance View
PCAS SA engages in the development, manufacture, and sale of chemicals. The company is headquartered in Ecully, Auvergne-Rhone-Alpes. The company operates through nine production sites and two main business units, Pharma Synthesis and Fine & Specialty Chemicals. Pharma Synthesis unit specializes in active pharmaceutical ingredients (API), intermediates and building blocks, and early phase services, among others. Fine & Specialty Chemicals unit focuses on custom manufacturing and proprietary products, such as fragrance, flavor ingredients, imaging and microelectronics chemicals. The firm operates several subsidiaries, including Saint-Jean Photochimie, Societe Bearnaise de Synthese, Expansia, PCAS BioMatrix Inc, based in Canada, and PCAS Finland Oy, based in Finland, among others.
See Also
What is Pcas SA's Total Current Liabilities?
Total Current Liabilities
217.1m
EUR
Based on the financial report for Jun 30, 2023, Pcas SA's Total Current Liabilities amounts to 217.1m EUR.
What is Pcas SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
14%
Over the last year, the Total Current Liabilities growth was -1%. The average annual Total Current Liabilities growth rates for Pcas SA have been 17% over the past three years , 26% over the past five years , and 14% over the past ten years .
You don't have any saved screeners yet
